Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial

Bone Marrow Transplantation
M KoenigsmannD Niederwieser

Abstract

Since the outcome of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) is highly variable, a risk-adapted treatment approach was evaluated. After two cycles of DHAP, patients received high-dose treosulfan/etoposide/carboplatinum (TEC) and autologous stem cell rescue. After TEC, low-risk patients with late relapse (>1 year after first CR who achieved CR after DHAP received no further treatment. Patients with late relapse who achieved CR or PR only after TEC underwent a second cycle of TEC. High-risk patients with early relapse/refractory disease received treosulfan/fludarabine followed by allogeneic transplantation. Rituximab was added in patients with B-cell lymphoma (86%). At entry, 36% of all 57 patients had refractory disease, 32% early and 32% late relapse. During DHAP treatment, progression occurred in 32% of patients. Of 33 patients who received TEC, 5 received second TEC and 15 allogeneic transplantation. Main toxicity after TEC was oral mucositis (CTC grades 3 and 4 in 50% and 13%, respectively). In total, 42% patients achieved CR. Median OS was 21.4 months for all patients and 32.6 for those who underwent allogeneic transplantation. International prognostic index (IPI) at study entry was highly discriminative...Continue Reading

References

Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C GuglielmiF Chauvin
Apr 24, 2001·Journal of Cancer Research and Clinical Oncology·P BojkoS Seeber
May 30, 2003·Bone Marrow Transplantation·P MolleeJ Lipton
Jul 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter H WiernikThomas M Habermann
Sep 4, 2008·Proceedings of the National Academy of Sciences of the United States of America·Georg LenzLouis M Staudt
Oct 24, 2008·Haematologica·Alejandro MartínUNKNOWN Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group)
Nov 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martee L HensleyLynn M Schuchter
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsty J ThomsonStephen Mackinnon
Oct 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Matthew UlricksonYi-Bin Chen
Oct 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Timothy S FenskeJulie M Vose
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-François LaroucheBertrand Coiffier
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marita ZiepertMarkus Loeffler
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jochen CasperMathias Freund
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz
Jan 14, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T E WitzigM S Czuczman
Sep 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine ThieblemontChristian Gisselbrecht
Aug 18, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alix O'MearaMartin Stern
Sep 26, 2012·Blood·Ulrike BacherUNKNOWN Lymphoma Working Committee of the CIBMTR

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.